Overview

INdians Followed for INtensive Lipid Lowering Treatment and Its safetY

Status:
Terminated
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
In South Asian Canadians with documented coronary artery disease or diabetes and hypercholesterolemia with LDL-C levels > 2.0 mmol/L after 4 weeks of monotherapy with any statin: To compare the percent (%) of patients who achieve an LDL-C concentration of 2.0mmol/L after a 6-week course of treatment with ezetimibe 10 mg/day co-administered with any statin at any dose versus doubling of the current statin dose.
Phase:
Phase 3
Details
Lead Sponsor:
Sunnybrook Health Sciences Centre
Collaborators:
Merck Frosst Canada Ltd.
Schering-Plough
Treatments:
Atorvastatin
Atorvastatin Calcium
Ezetimibe
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Rosuvastatin Calcium
Simvastatin